ISRG earnings analysis — 8-K, transcript, guidanceIntuitive Surgical, Inc. (ISRG) 财报解读 — 8-K、transcript、guidance
Intuitive Surgical (ISRG) Q2 2026 Earnings Follow-Up Analysis
Earnings Beat vs Consensus
Per the company’s July 16 GlobeNewswire official release and SEC 8-K filing, Q2 2026 revenue hit $2.9B, beating the consensus estimate of $2.8B (+2.4%). Non-GAAP EPS came in at $2.80, exceeding the $2.48 consensus (+12.9%), while GAAP EPS was $2.29.
Revenue Quality and Profitability
Q2 revenue grew 19% YoY per official filings, with a gross margin of 67.8%, operating margin of 33.6%, and 13.6% YoY growth in operating income. EBITDA margin was 29.4%, GAAP net income was $818M with a 28.3% net margin. Non-GAAP net income included a $28M after-tax tariff refund benefit, equal to $0.08 per diluted share.
Cash Flow and Capital Allocation
Q2 operating cash flow was $912M, capex totaled $103M, and free cash flow hit $809M. The company ended the quarter with $8.6B in cash and no outstanding debt, resulting in net cash of $8.6B. The firm repurchased 0.9M common shares for $380M during the quarter.
Forward Guidance
The company provided 2026 full-year non-GAAP guidance: global da Vinci procedure growth of 13.5% to 15.5%, non-GAAP gross margin between 68.0% and 69.0% (including a 1% estimated tariff impact), and non-GAAP operating expense growth of 11% to 13%. No GAAP forward guidance was provided, and no indication of a prior guidance adjustment was given, so no clear raise or cut was confirmed.
GAAP vs Non-GAAP Reconciliation
Official filings note differences between GAAP and non-GAAP EPS stem from non-recurring items like the tariff refund and share-based compensation expenses.
Management Commentary
Per the Q2 2026 earnings call transcript, U.S. da Vinci procedures grew 12% but slowed due to deferred patient care; international growth hit 20%, with China facing reduced tender activity, local competition, and pricing pressure, while Japan’s new policies and India’s da Vinci 5 clearance supported growth. Ion procedures rose 36% YoY, da Vinci 5 system placements increased, and a new extended instrument use program was launched to lower customer costs.
Unresolved Investor Questions
This analysis lacks segment-specific revenue data, backlog/RPO figures, deferred revenue details, capex breakdowns, and full 10-Q filing details. No GAAP forward guidance was provided, leaving gaps in full visibility into expected performance under U.S. GAAP rules.
直觉外科（ISRG）2026年第二季度收益后续分析
业绩超预期情况
根据公司7月16日发布的官方公告及SEC 8-K文件，二季度实际营收29亿美元，超出市场一致预期的28亿美元（+2.4%）；非GAAP每股收益2.80美元，超出预期的2.48美元（+12.9%），GAAP每股收益为2.29美元。
营收质量与盈利能力
二季度营收同比增长19%（官方披露），总毛利率67.8%，营业利润率33.6%，营业利润同比增长13.6%。EBITDA利润率29.4%，GAAP净利润8.18亿美元，净利率28.3%。非GAAP净利润含2800万美元税后关税退税收益，对应每股0.08美元。
现金流与资本配置
二季度经营现金流9.12亿美元，资本支出1.03亿美元，自由现金流8.09亿美元。期末现金及等价物达86亿美元，无带息债务，净负债为-86亿美元。季度内回购0.9百万股普通股，耗资3.8亿美元。
业绩指引
公司提供2026财年非GAAP指引：全球达芬奇手术量增长13.5%-15.5%，非GAAP毛利率区间68%-69%（含1%的关税负面影响），非GAAP营业费用增长11%-13%。未提供GAAP指引，且未披露此前指引调整情况，无明确上调或下调信号。
GAAP与非GAAP差异
官方披露两者每股收益差异主要源于关税退税、股权激励费用等非经常性或调整项。
管理层评论
根据电话会议 transcript，美国达芬奇手术量增长12%但受患者延迟就医影响增速放缓；海外市场增长20%，中国市场面临招标减少、本土竞争及定价压力，日本新政策利好，印度市场获达芬奇5系统准入。ION手术量同比增长36%，达芬奇5系统装机量提升，推出仪器延长使用计划以降低客户成本，单端口平台手术量增长61%。
未明确事项
未披露细分业务（如仪器、系统）的单独营收数据、订单储备/递延收入、资本支出的具体使用计划，未提供完整季度10-Q文件细节，且指引未包含GAAP数值，投资者无法获取完整的GAAP预期表现。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。